- Home
- / HCW Biologics
HCW Biologics
Stock Price
$0.6
2024-08-08
Market Capitalization
$22.6 M
2024-08-08
Revenue
$2.8 M
FY, 2023
HCW Biologics Summary
Company Summary
- Overview
- HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction. It focuses on treatments of cancer, inflamm-aging, and aging-associated diseases. The company aims to offer product candidates to address inflammasomes and senescence simultaneously.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Miramar, FL, US | view all locations
- Website
- https://hcwbiologics.com/
- Cybersecurity rating
Table of Contents
Key People
Peter Rhode, Chief Scientific Officer, Vice President of Clinical Operations
Rebecca Byam, Chief Financial Officer
HCW Biologics Financials
Summary Financials
- Revenue (Q1, 2024)
- $1.1M
- Gross profit (Q1, 2024)
- $614.7K
- Net income (Q1, 2024)
- ($7.5M)
- Cash (Q1, 2024)
- $4.1M
- EBIT (Q1, 2024)
- ($7.5M)
- Enterprise value
- $25.5M